


**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

22-386

**RISK ASSESSMENT and RISK MITIGATION
REVIEW(S)**



**Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Surveillance and Epidemiology**

Date: April 3, 2008

To: Mary Parks, M.D., Director
Division of Metabolic and Endocrine Drug Products (DMEP)

Thru: Claudia Karwoski, Pharm.D., Acting Director
Division of Risk Management (DRISK)

From: OSE PrandiMet Risk Management Team
Scientific Lead: Jeanine Best, MSN, RN, PNP, Senior Drug Risk
Management Analyst, OSE-DRISK

Cheryl Campbell, MS, Regulatory Project Manager, OSE-IO
Mary Dempsey, Risk Management Coordinator, OSE-DRISK
Felecia Duffy, RN, BSN, MSEd, Safety Evaluator, OSE-DMEDP
Joslyn Swann, PharmD, MGA, Safety Evaluator, OSE-DAEA

Subject: Review of Risk Management Plan

Drug Name(s): PrandiMet (repaglinide and metformin HCL) Tablets

Application Type/Number: NDA 22-232

Applicant/sponsor: Novo Nordisk

OSE RCM #: 2007-2163

1 INTRODUCTION

This memorandum follows a request from the Division of Metabolic and Endocrine Products (DMEP) for the Office of Surveillance and Epidemiology (OSE) to review and comment on the PrandiMet (repaglinide and metformin HCL) Tablets Risk Management Plan (RMP) submitted to FDA by Novo Nordisk on August 15, 2007, as part of the original New Drug Application (NDA) 22-232.

PrandiMet is the fixed dose combination product of repaglinide (Prandin) and metformin HCL (Glucophage) and is submitted for the indication of an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus where treatment with dual repaglinide and metformin therapy is appropriate. Novo Nordisk submitted two fixed-dose strengths: 1 mg repaglinide/500 metformin HCL (1/500) and 2 mg repaglinide/500 metformin HCL (2/500).

2 MATERIAL REVIEWED

- Risk Management Plan submitted with NDA 22-232, PrandiMet (repaglinide and metformin HCL) Tablets, dated August 15, 2007.

3 RESULTS OF REVIEW

3.1 SAFETY CONCERNS

The risks of repaglinide and metformin HCL are well delineated as both products have been marketed for more than 10 years. The major risks associated with repaglinide include hypoglycemia, abdominal pain, and nausea. The major risk associated with metformin HCL is lactic acidosis.

3.2 PROPOSED RISK MINIMIZATION ACTIVITIES

Novo Nordisk proposes routine risk minimization activities including labeling and routine pharmacovigilance. Labeling and routine pharmacovigilance are the current risk minimization activities for the approved individual products, repaglinide and metformin HCL.

4 CONCLUSIONS

The Sponsor's submission does not constitute a formal Risk Minimization Action Plan (RiskMAP). We agree with the Sponsor that routine risk minimization activities for PrandiMet are adequate at this time based on the currently identified and potential risks of the product. No additional safety concerns have been identified at this time by either OSE or DMEP that warrant consideration of a formal RiskMAP or additional risk minimization activities.

If DMEP identifies additional safety concerns that warrant risk minimization activities above labeling and routine pharmacovigilance, or a formal RiskMAP, please re-consult OSE/Division of Risk Management.

OSE/DMEDP (Division of Medication Error and Prevention) will provide a separate review encompassing the tradename review and potential medication errors.

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Jeanine Best
4/3/2008 07:25:54 AM
DRUG SAFETY OFFICE REVIEWER

Claudia Karwoski
4/4/2008 12:50:57 PM
DRUG SAFETY OFFICE REVIEWER